Ichino N et al. A new index for liver fibrosis
management of chronic hepatitis C, since the treatment and prognosis of chronic hepatitis depend on the fibrosis stage[1]. In chronic viral hepatitis, the presence of signifi-cant fibrosis (F ≥ 2) indicates the need for antiviral thera-pies, and the outcome of therapy should be assessed by the improvement in fibrosis stage. Furthermore, the risk of hepatocellar carcinoma or bleeding from esophageal varices is high in patients with advanced fibrosis[2,3]. Liver biopsy is the gold standard for the assessment of fibrosis stage in chronic hepatitis. However, liver biopsy is an in-vasive and expensive procedure, and its accuracy is some-times questionable because of sampling errors, inadequate specimens and the subjectivity of diagnosis[4,5].
Non-invasive assessment of liver fibrosis is a major objective that has been encouraging many approaches, such as routine laboratory tests and serum markers of fibrosis[6-12]. The aminotransferase-to-platelet ratio index (APRI)[11], the Forns index[6], the FibroTest[7] and the Fi-broIndex[12] have been proposed for use as non-invasive fibrosis indices. Transient elastography with the use of a new apparatus, FibroScan (EchoSens, Paris, France) for measurement of liver stiffness (LS) has been developed[13]. LS measured by FibroScan has been reported to correlate with stage of fibrosis in various liver diseases[13-24]. It was used for assessing the effect of treatment in chronic hepa-titis C[25].
In the present study, we developed a new fibrosis index, the Fibro-Stiffness index, consisting of LS, platelet count and prothrombin time from 165 patients with chronic hepatitis C (estimation group) to improve the diagnostic efficacy of LS. We also tried a combination of Fibro-Stiffness index and routinely available laboratory tests to improve its diagnostic performance. These results in the estimation group were validated in 120 patients with chronic hepatitis C (validation group).
Liver stiffness measurement
LS measurement by transient elastography was performed with FibroScan (EchoSens, Paris, France) within a week of liver biopsy. FibroScan is equipped with a probe in-cluding an ultrasonic transducer and a vibrator. A vibra-tion of mild amplitude and low frequency is transmitted from the vibrator placed on the body surface toward the liver through the intercostal space. The vibration induces an elastic shear wave that propagates through the liver tissue. The pulse-echo ultrasound acquisitions follow the propagation of the shear wave and determine its veloc-ity. The velocity is directly related to tissue stiffness; the harder the tissue, the faster the shear wave propagates. LS is calculated from velocity and expressed in kilopascals (kPa). Ten successful acquisitions were performed on each measurement, and the median value was adopted as repre-sentative of LS.
Statistical analysis
The end point was the discrimination between F0 and F1-4, between F0-1 and F2-4, between F0-2 and F3-4 and between F0-3 and F4, using a combination of LS and rele-vant biochemical or hematological variables. Variables that correlated significantly with fibrosis stage in the estima-tion group were identified by univariate analyses (analysis of variance). Then the independent predictors of fibrosis stage were assessed by multiple regression analysis (ordinal logistic regression). A predictive index was constructed by modeling the values of the independent variables and their coefficient of regression. The difference of fibrosis indices between neighboring fibrosis stages were estimat-ed by the Tukey-Kramer test. The optimal discriminate cut-off values of each fibrosis index were assessed from the area under the receiver operating characteristics (ROC) curves (AUCs). The optimal discriminating cut-off values were determined at the maximum total of sensitivity and specificity. The statistical analysis was performed by JMP® (SAS Institute, Cary, NC, USA).
MATERIALS AND METHODS
Patients
In 285 consecutive patients with chronic hepatitis C virus infection, liver biopsy was performed at Fujita Health Uni-versity Hospital from July 2004 to February 2009 (Table 1). From July 2004 to September 2007, 165 of these pa-tients (estimation group) were used to develop the Fibro-Stiffness index. From October 2007 to February 2009, the other 120 patients (validation group) were used to validate the diagnostic performance of the Fibro-Stiffness index. The usefulness of the Fibro-Stiffness index was compared with LS, the APRI, the Forns index and the FibroIndex. Clinical data were collected within 3 d of liver bi-opsy. Sections were stained with hematoxylin-eosin stain and Azan stain. Liver biopsy specimens were assessed by 2 hepatologists (Yoshioka K and Kawabe N). When fibrosis stages evaluated by 2 hepatologists differed, the higher fibrosis stage was adopted. Fibrosis stage, deter-mined according to the METAVIR score, was classified as F0, no fibrosis; F1, portal fibrosis without septa; F2, few septa; F3, numerous septa without cirrhosis; and F4, cirrhosis.
RESULTS
Development of the Fibro-Stiffness Index
LS, platelet count, prothrombin time, aspartate amino-transferase (AST), alanine aminotransferase (ALT), albu-min, γ globulin, total cholesterol and hyaluronic acid were significantly correlated with fibrosis stage in the estimation group (Table 2). Among these variables, LS (P < 0.0001), platelet count (P = 0.0408), and prothrombin time (P = 0.0066) were identified as independent predictors of fibrosis stage by multiple regression analysis (Table 3). By multiple regression analysis, the estimated values of LS, platelet count and prothrombin time were calculated as -0.2662, 0.0749 and 0.0560, respectively. The optimum intercept was also calculated as 5.7710. Thus the Fibro-Stiffness index was constructed with these 3 variables: Fi-bro-Stiffness index = 5.7710 - 0.2662 [LS (kPa)] + 0.0749 [platelet count (× 104/mL)] + 0.0560 [prothrombin time (%)].
WJG|doc.guandang.net 14, 2010|Volume 16|Issue 38|
for the assessment of liver fibrosis 2.1.1 ...? Liver biopsy is an invasive procedure, with ... A new index for non-in... 暂无评价 8页 ...
is? a? promising? non-invasive? (ELF)? test? to? predict? liver? ...as?diagnostic?tools?for?the?assessment?of?liver?fibrosis.? The?ELF?test?...
FEASIBILITY OF DIAGNOSING AND STAGING LIVER FIBROSIS WITH DIFFUSION WEIGHTED IMAGING_专业资料。维普资讯 http://www.cqvip.com Chni Me Si dcJSetmbr08pee 20 ...
MR Elastography of Liver Fibrosis Huwart et al A ll chronic liver ...Liver ?brosis: non-invasive assessment with MR elastography. NMR Biomed 2006...
A Device for Non-invasive On-site Sampling of Cattle Breath with Solid-...Assessment of the effects of feed, health status, age and other important ...
(qHBsAg) * Non-invasive assessment of hepatic fibrosis * HBV subgenotypes/...patient receiving a liver from antive HBc (+) donor should receive long-...
NON-INVASIVE ASSESSMENT OF MUSCLE STIFFNESS IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY EON, LILIAN LACOURPAILLE, MSc,1 FRANC ?OIS HUG, PhD,1,2...
Changes of non -invasive markers and FibroScan values during HCV treatment [...FibroScan: a noninvasive test of liver fibrosis assessment[J]. Saudi J ...
In this research, a new device for on-site, non-invasive animal breath ...Assessment of the effects of feed, health status, age and other important ...
热门文档